Opus Genetics vs Tonix Pharmaceuticals
Opus Genetics reported revenue of $14 million in fiscal 2025, about the same as Tonix Pharmaceuticals' $13 million in fiscal 2025. Opus Genetics' revenue grew 29.1% in its latest year, and Tonix Pharmaceuticals' grew 29.9%. Opus Genetics had an operating margin of -271.9%, against -959.0% at Tonix Pharmaceuticals.
Side by side
| Opus Genetics | Tonix Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $14M | $13M |
| Revenue growth | 29.1% | 29.9% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | 49.3% |
| Operating margin | −271.9% | −959.0% |
| Net margin | −349.3% | −946.2% |
| Free cash flow | — | −$103M |
| Free cash flow margin | — | −787.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $14M |
| Change in diluted share count | 132.9% | 1,055.9% |
| Last close | $4.08 | $2.55 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $323,890, sold $16.6 million | bought $458,758, sold $0 |
| Piotroski F-score | 3 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Opus GeneticsTonix Pharmaceuticals
Operating margin
Percent of revenue
Opus GeneticsTonix Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Opus GeneticsTonix Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Opus Genetics and Tonix Pharmaceuticals pages.